Resilient Argenx stock holds near record highs after Forte Biosciences acquisition
Published on 08/28/2026 at 16:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx SE (NL0010832176) stock is holding close to record territory in late August 2026, as investors digest the completed acquisition of Forte Biosciences and a wave of analyst target hikes that reflect confidence in the company’s immunology strategy as of August 28, 2026.
The shares recently set a fresh all-time high at $1,059.86 for the ADR and remain supported by the closure of the Forte Biosciences transaction on August 27, 2026, which adds the CD122 antibody FB102 to Argenx’s pipeline and reinforces the growth narrative in autoimmune and inflammatory diseases.
For investors, the combination of a record price level, a $1.6 billion deal, and higher analyst expectations underlines how the market now prices Argenx as a leading rare disease player with expanding optionality beyond its flagship therapy.
Forte Biosciences deal closes and expands the pipeline
Argenx has officially completed its acquisition of Forte Biosciences, Inc., a transaction that was structured around a $1.6 billion consideration and closed on August 27, 2026, following the expiration of the tender offer a day earlier. As reported in the deal overview, the tender offer that expired just after 11:59 p.m. Eastern Time on August 26, 2026 resulted in 19,894,879 Forte shares being validly tendered and not withdrawn, representing 87.13 percent of the outstanding common stock at that point, which gave Argenx effective control of the asset base.
The merger mechanics mean Forte Biosciences is now a wholly owned subsidiary of Argenx, and Forte’s common stock has been removed from trading on the Nasdaq Capital Market, simplifying the group’s structure as it integrates the acquired programs and personnel into its broader immunology platform. This step also locks in Argenx’s access to FB102, a first in class anti CD122 antibody, which is seen as a strategic complement to Vyvgart and other internal programs targeting dysregulated immune pathways.
One key detail for investors is the price paid at the tender stage, with Forte shareholders receiving $77 per share in cash for each of their holdings, providing a concrete valuation signal for the acquired pipeline. By paying that fixed cash amount per share, Argenx is making an explicit bet on the commercial and clinical potential of FB102 and related assets, and the total $1.6 billion outlay underscores that this is a meaningful bolt on rather than a small tuck in acquisition.
Analyst targets and recent price action support Argenx stock
The stock market reaction to the Forte completion and recent clinical updates has been visible in the share price performance, with Argenx’s ADRs hitting an all time high of $1,059.86 during the latest rally phase. This new peak compares with the last reported closing level of $1,057.08, meaning the intraday high stood $2.78 above that close, and it places the shares only a small distance beyond the earlier 52 week high near $1,058 reported on August 27, 2026.
On the home market, real time data from late August 2026 show the Brussels listing around EUR 900.20, with the year to date performance in that snapshot at 25.83 percent and the five day change at 1.44 percent, indicating that the stock has not just spiked on a single headline but has been building gains more gradually through the year. Another intraday quote on August 28, 2026 on a European trading venue points to the shares changing hands around EUR 901.80 to EUR 903.00, with the one day variation slightly negative at between minus 0.48 percent and minus 0.62 percent but the year to date change still close to 25.95 percent to 25.98 percent, illustrating that minor short term fluctuations have not altered the broader uptrend.
Alongside this price action, analysts have been adjusting their views to reflect higher earnings expectations from Vyvgart and the broader portfolio. One coverage benchmark has raised its target for Argenx to $1,400 while assigning a Buy rating, another has taken its objective to $1,353 with a similar positive stance, and other firms have lifted their price targets to levels such as $1,100 and $1,200, sometimes maintaining Outperform or equivalent ratings even when they have become more cautious on valuation. These figures compared with the prior share levels just above $1,050 suggest that equity research now embeds upside of between $43 and $343 per share versus the recent $1,057.08 close, and that consensus thinking is increasingly framed around continued revenue expansion into fiscal 2027 rather than a plateau.
Vyvgart as the commercial engine
Central to this evolving thesis is Vyvgart, Argenx’s key commercial product for generalized myasthenia gravis and other rare autoimmune conditions, which has been driving both reported revenue growth and the confidence behind the recent target revisions. Analysts raising their numbers have cited successful launches and expansions of Vyvgart in multiple rare disease indications as a core justification for price targets such as $1,400 and $1,353, explicitly stating that higher Vyvgart revenue expectations for fiscal 2027 underpin the assumptions behind those targets.
Recent clinical milestones also reinforce Vyvgart’s profile. Data from the Phase 3 ALKIVIA trial in myositis showed that the study met its primary endpoint, bolstering the argument that the drug’s mechanism of action can be extended beyond its original uses. Commentary on this dataset points out that Vyvgart achieved statistically significant results in sub analyses, including in subsets related to immune mediated necrotizing myopathy, which in turn helps justify forecasts that see the therapy contributing a larger share of Argenx’s top line across the next couple of years.
While the exact quarterly revenue splits for Vyvgart are not detailed in the latest media summaries, references to higher expected fiscal 2027 revenue and the repeated emphasis on rare disease launches show that the drug is now treated as a multi indication platform rather than a single product. For valuation, that matters because the more indications Vyvgart can serve successfully, the longer and broader its sales curve becomes, and the more support Argenx has for maintaining double digit percentage improvements in annual revenue.
Recent clinical and corporate milestones
The Forte acquisition fits into a broader pattern of clinical and corporate milestones that have accumulated through August 2026. Earlier in the month, Argenx communicated success in a Phase 3 clinical program targeting autoimmune muscle inflammation, which is consistent with the myositis focus evident in the ALKIVIA data. That success has been highlighted through earnings related commentary in mid August, where the company presented Vyvgart’s Phase 3 results as a significant breakthrough in treating autoimmune myositis and as a support for its long term pipeline strategy.
Additionally, the company has scheduled an extraordinary general meeting for September 17, 2026 with an agenda that includes the appointment of two new outside directors, signaling that governance and board composition are being actively managed in light of the company’s growing scale. This meeting will follow the full integration of Forte Biosciences, and the new directors are expected to contribute expertise suitable for overseeing a larger and more complex portfolio of clinical and commercial programs.
Structurally, the completion of the Forte transaction and the governance changes mean Argenx is transitioning further into the role of a diversified immunology company with multiple clinical bets in autoimmune disease, an established commercial engine in Vyvgart, and a more global footprint in terms of management and shareholder base. For investors, each confirmed milestone reduces execution uncertainty for specific programs while also raising the stakes in integration and lifecycle management.
Valuation context at current levels
With Argenx shares near record highs and the Brussels quotation showing gains of more than 25 percent since the start of 2026, the valuation question becomes more pressing. One metric that investors often examine is the difference between current share price and the range of analyst targets; with the ADR closing at $1,057.08 and recent price objectives running from $1,100 up to $1,400, the implied upside spans roughly 4 percent at the low end through more than 32 percent at the high end, assuming the stock stays close to that prior close.
At the same time, the home market price around EUR 900.20 and intraday levels slightly above EUR 901 suggest that currency adjusted valuation has climbed substantially from earlier in the year, when the year to date gain was much lower. The reported 25.83 percent improvement year to date in one late August snapshot underscores that much of the move has come in recent months, particularly around the confirmation of clinical successes and corporate transactions like the Forte acquisition.
The balance of analyst opinion reflects this tension between high expectations and a strong recent run. Some firms have introduced more cautious ratings such as Hold after sustained share price appreciation, even while lifting their price targets from prior levels by several percent, whereas others continue to recommend buying the stock on the premise that Vyvgart’s expansion and FB102’s potential justify stretching valuation multiples. In that sense, the stock’s ability to remain close to $1,059.86 without swift mean reversion reveals that investors broadly accept the current pricing of Argenx as reasonable for a company with multi year growth options.
Vyvgart as a representative product
Vyvgart stands as Argenx’s flagship product and a representative example of the company’s business model, which centers on using antibody based therapies to modulate immune responses in rare autoimmune diseases. Initially approved for generalized myasthenia gravis, Vyvgart has been rolled out in additional indications where pathogenic antibodies play a critical role, backing Argenx’s belief that focused modulation of immune pathways can deliver clinically meaningful benefits in conditions with limited treatment options.
From a commercial perspective, Vyvgart’s growth reflects both new patient starts and geographic expansion, as launch sequences in different regions add revenue layers over time. The therapy’s success in Phase 3 trials such as ALKIVIA and related myositis programs signals that the drug has a viable path into further autoimmune segments, strengthening Argenx’s ability to sustain a growing revenue base supported by a single, versatile platform.
Argenx stock price context
As of the most recent completed trading session on August 27, 2026, Argenx’s ADR closed at $1,058.30 after touching an intraday high of $1,061.13, levels that are close to the record $1,059.86 high reported in the latest coverage and that emphasize how the stock is trading in a tight band around its best ever prices.
This positioning at the upper edge of its historical range, combined with evidence of year to date gains above 25 percent in the Brussels listing, gives investors a clear marker for evaluating future moves in Argenx stock against the backdrop of further clinical data and integration progress from the Forte Biosciences transaction.
Fact box
Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq (ADR) / Euronext Brussels
Price (as of August 27, 2026, 4:00 p.m. ET): $1,058.30 USD
Sector / Industry: Biotechnology
